In the present study, we challenged two RMS cell lines (the RD and RH30 cells, representing the ERMS and ARMS subtypes, respectively) with new pyrazolo[3,4-d]pyrimidine derivative SFK inhibitors, whose efficacy was previously demonstrated in several tumor types [9–12]. The gene discussed is KIDINS220; the disease is neoplasm.